Ranbaxy Could Lose Diovan Generic Exclusivity In Mylan U.S. Court Suit
This article was originally published in PharmAsia News
Ranbaxy Laboratories is watching closely a suit filed by Mylan against U.S. FDA for denying its application for a generic of the Novartis hypertension drug Diovan (valsartan) to compete with Ranbaxy's generic.
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"